Prevalence of pretreatment drug resistance in persons initiating and reinitiating antiretroviral therapy in Sri Lanka: results from a national representative survey

Abstract

Abstract Background We conducted a nationwide cross-sectional study to estimate pretreatment drug resistance (PDR) prevalence in adults initiating ART in Sri Lanka following the WHO’s recommendations. Methods HIV drug resistance was determined on dried blood spots (DBSs) using population-based sequencing of the protease and reverse transcriptase genes and interpretation was based on Stanford HIVdb v9.0. Analyses were weighted to adjust for multistage sampling and genotypic failure rate. We used logistic regression to assess differences between groups. Results Overall, in 10% (15 of 150) of patients initiating ART, HIV drug resistance mutations were detected. The prevalence of resistance to NNRTI drugs efavirenz/nevirapine was 8.4% (95% CI 4.6–15.0) but differed among those reporting having prior antiretroviral (ARV) exposure (24.4%, 95% CI 13.8–39.5) compared with 4.6% (95% CI 1.6–12.8) for those reporting as being ARV naive (OR 4.6, 95% CI 1.3–16.6, P = 0.021). PDR to efavirenz/nevirapine was also nearly twice as high among women (14.1%, 95% CI 6.1–29.4) compared with men (7.0%, 95% CI 3.1–14.7) (P = 0.340) and three times high among heterosexuals (10.4%, 95% CI 2.4–35.4) compared with MSM (3.8%, 95% CI 1.1–12.7) (P = 0.028). NRTI PDR prevalence was 3.8% (95% CI 1.1–12.1) and no PI PDR was observed in the study. Conclusions A high prevalence of efavirenz/nevirapine PDR was reported, especially in patients with prior ARV exposure, in women and those reporting being heterosexual. These findings highlight the need to fast-track the transition to the WHO-recommended dolutegravir-based first-line ART.